Publikationen
Unsere Forschungsergebnisse erscheinen in internationalen Publikationen in Peer-Reviewed Journals, außerdem in Kongressbeiträgen, Vorträgen und Postern und wissenschaftlichen Fachveranstaltungen.
Übersicht über unsere Publikationen
Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM.
Valent P, Hartmann K, Hoermann G, Reiter A, Alvarez-Twose I, Brockow K, Bonadonna P, Hermine O, Niedoszytko M, Carter MC, Butterfield JH, Siebenhaar F, Zanotti R, Radia DH, Castells M, Sperr WR, Broesby-Olsen S, Triggiani M, Schwartz LB, George TI, Gülen T, Sotlar K, Gotlib J, Galli SJ, Horny HP, Metcalfe DD, Orfao A, Arock M, Akin C. Harmonization of Diagnostic Criteria in Mastocytosis for Use in Clinical Practice: WHO vs ICC vs AIM/ECNM. J Allergy Clin Immunol Pract. 2024.
Mehr erfahrenSpatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma.
John M, Helal M, Duell J, Mattavelli G, Stanojkovska E, Afrin N, Leipold AM, Steinhardt MJ, Zhou X, Žihala D, Anilkumar Sithara A, Mersi J, Waldschmidt JM, Riedhammer C, Kadel SK, Truger M, Werner RA, Haferlach C, Einsele H, Kretzschmar K, Jelínek T, Rosenwald A, Kortüm KM, Riedel A, Rasche L. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. Blood. 2024.
Mehr erfahrenFlow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines.
Monaghan SA, Eck S, Bunting S, Dong XX, Durso RJ, Gonneau C, Hays A, Illingworth A, League SC, Linskens E, McCausland M, McCloskey TW, Rolf N, Shi M, Wallace PK, Litwin V, Kern W, Deeb G, Nash V, Olteanu H. Flow cytometry assay modifications: Recommendations for method validation based on CLSI H62 guidelines . Cytometry B Clin Cytom. 2024.
Mehr erfahrenInfluence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion.
Montoro MJ, Palomo L, Haferlach C, Acha P, Chan O, Navarro V, Kubota Y, Schulz FI, Meggendorfer M, Briski R, Al-Ali N, Xicoy B, Lopez F, Bosch F, González T, Eder LN, Jerez A, Wang YH, Campagna A, Santini V, Bernal Del Castillo T, Such E, Tien HF, Díaz Varela N, Platzbecker U, Haase DT, Díez-Campelo M, Della Porta MG, Garcia-Manero G, Wiseman DH, Germing U, Maciejewski JP, Komrokji RS, Sole F, Haferlach T, Valcárcel D. Influence of TP53 Gene Mutations and its Allelic Status in Myelodysplastic Syndromes with Isolated 5q Deletion. Blood. 2024.
Mehr erfahrenImplementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtain.
Devitt KA, Kern W, Kajstura MA, Holl EK, Hays AL, Hedley BD, Gonneau C, Jellison ER, McCloskey TW, Mishra S, Rebeles J, Ouseph MM. Implementation of flow cytometry testing on rare matrix samples: Special considerations and best practices when the sample is unique or difficult to obtain. Cytometry B Clin Cytom. 2024.
Mehr erfahrenSubunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes.
Jann JC, Hergott CB, Winkler M, Liu Y, Braun B, Charles A, Copson KM, Barua S, Meggendorfer M, Nadarajah N, Shimony S, Winer ES, Wadleigh M, Stone RM, DeAngelo DJ, Garcia JS, Haferlach T, Lindsley RC, Luskin MR, Stahl M, Tothova Z. Subunit-specific analysis of cohesin-mutant myeloid malignancies reveals distinct ontogeny and outcomes. Leukemia. 2024.
Mehr erfahrenFBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells.
Sperk A, Gabriel A, Koch D, Augsburger A, Sanchez V, Brockelt D, Öllinger R, Engleitner T, Giansanti P, Ludwig R, Auf der Maur P, Walter W, Haferlach T, Jeremias I, Rad R, Steigenberger B, Kuster B, Eichner R, Bassermann F. FBXL6 is a vulnerability in AML and unmasks proteolytic cleavage as a major experimental pitfall in myeloid cells. Leukemia. 2024.
Mehr erfahren